Dale G Ando Net Worth

The estimated Net Worth of Dale G Ando is at least $1.08 Milion dollars as of 5 June 2015. Dale Ando owns over 15,000 units of Sangamo Therapeutics Inc stock worth over $93,881 and over the last 19 years Dale sold SGMO stock worth over $984,180.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dale Ando SGMO stock SEC Form 4 insiders trading

Dale has made over 34 trades of the Sangamo Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Dale exercised 15,000 units of SGMO stock worth $51,750 on 5 June 2015.

The largest trade Dale's ever made was selling 20,000 units of Sangamo Therapeutics Inc stock on 26 October 2012 worth over $114,000. On average, Dale trades about 10,557 units every 25 days since 2005. As of 5 June 2015 Dale still owns at least 111,763 units of Sangamo Therapeutics Inc stock.

You can see the complete history of Dale Ando stock trades at the bottom of the page.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp oraz Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.

What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Complete history of Dale Ando stock trades at Sangamo Therapeutics Inc

Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:

• Alexander Macrae,
  President, Chief Executive Officer, Director
• Sung Lee,
  Chief Financial Officer, Executive Vice President
• Gary Loeb,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
  CEO, Pres & Director
• R. Andrew Ramelmeier,
  Executive Vice President - Technical Operations
• Dr. R. Andrew Ramelmeier Ph.D.,
  Exec. VP of Technical Operations
• D. Mark McClung,
  Exec. VP & COO
• James Meyers,
  Independent Director
• H. Stewart Parker,
  Independent Director
• Joseph Zakrzewski,
  Independent Director
• Robert Carey,
  Independent Director
• Saira Ramasastry,
  Independent Director
• Karen Smith,
  Independent Director
• McDavid Stilwell,
  IR Contact Officer
• John Markels,
  Independent Director
• Kenneth Hillan,
  Director
• Prathyusha Duraibabu,
  Vice President - Finance
• D. Mark McClung,
  Executive Vice President, Chief Business Officer
• Scott B. Willoughby,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Prathyusha Duraibabu CPA, M.B.A.,
  Sr. VP, CFO & Principal Accounting Officer
• Dr. Jason D. Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Prathyusha Duraibabu,
  VP of Fin., Principal Accounting Officer & Principal Financial Officer
• Dr. Duncan McKay,
  Sr. VP & GM of Europe
• Heather Erickson,
  Chief of Staff
• Dr. Nathalie Dubois-Stringfellow,
  Sr. VP of Product Devel. & Management
• Whitney Jones,
  Sr. VP & Chief People Officer
• Aron Feingold,
  Head of Corp. Communications & Investor Relations Officer
• Dr. Jason Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Stephen George Dilly,
  Director
• Paul B Cleveland,
  Director
• Henry Ward Wolff,
  Director
• Steven J Mento,
  Director
• William R Ringo,
  Director
• Geoffrey Nichol,
  Executive Vice President, R&D
• Curt A. Iii Herberts,
  Sr.VP & Chief Business Officer
• Dale G Ando,
  VP, Therapeutic Dev. & CMO
• Edward R. Conner,
  Sr. VP & Chief Medical Officer
• Thomas G Wiggans,
  Director
• William G Gerber,
  Director
• Roger Jeffs,
  Director
• Heather D Turner,
  EVP, General Counsel & Sec.
• Robert J. Schott,
  SVP, Head of Development
• Stephane Boissel,
  EVP, Corp. Strategy
• Kathy Yi,
  EVP & Chief Financial Officer
• Margaret Liu,
  Director
• Michael C Wood,
  Director
• Greg Zante,
  Sr Dir., Finance and Admin
• Le Roy C Kopp,
  10% owner
• Edward O Ii Lanphier,
  President and CEO
• Jon E M Jacoby,
  Director
• Casey C Case,
  Vice President, Research
• Peter Bluford,
  V.P., Corporate Development
• William J Rutter,
  Director
• John William Larson,
  Director
• Philip D Gregory,
  Vice President, Research
• Capital Management, L.P.Ra ...,
  
• David G Ichikawa,
  Senior VP, Bus. Dev.
• Jason D. Fontenot,
  SVP, Chief Scientific Officer
• Scott B. Willoughby,
  SVP, GEN. COUNSEL & SECRETARY
• Inc.Biogen Ma Inc. Biogen,
  
• Sandy Macrae,
  PRESIDENT, CEO AND DIRECTOR
• Nathalie Dubois Stringfellow,
  SVP-CHIEF DEVELOPMENT OFFICER
• Amy Pooler,
  VP, HEAD OF RESEARCH
• Courtney Beers,
  
• Margaret A Horn,